publication . Conference object . 2020

BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexed-based chemotherapy

Vasiliki Panou; Amber Louw; Weronika Maria Szejniuk; Christos Meristoudis; Siaw Ming Chai; Louise Andersen; Azadeh Birbaneh Asghari; Mogens Vyberg; Johnni Hansen; Jenette Creaney; ...
Closed Access English
  • Published: 07 Sep 2020
  • Country: Denmark
BRCA1-associated protein 1 (BAP1) immunohistochemistry (IHC) was assessed as a predictive biomarker for pemetrexed-based treatment in non-surgically treated malignant pleural mesothelioma (MM) patients.IHC was performed on 168 MM patient slides to assess BAP1 loss (BAP1-) or retain (BAP1+). BAP1 mouse monoclonal antibody (C-4) was used. Gender, age, performance status (PS), subtype, types of treatment and overall survival (OS) was retrieved from medical records and registries. Clinical endpoint was OS. Data were analyzed by Fisher´s exact test, Kaplan-Meier estimate, log rank test and cox regression.In total, 91 MM patients that received best supportive care (BS...
Persistent Identifiers
free text keywords: Performance status, Clinical endpoint, Pemetrexed, medicine.drug, medicine, Proportional hazards model, Mesothelioma, medicine.disease, Log-rank test, Chemotherapy, medicine.medical_treatment, Oncology, medicine.medical_specialty, Internal medicine, Exact test, business.industry, business
  • COVID-19
Any information missing or wrong?Report an Issue